Assembly Biosciences, Inc. operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States. It is involved in the development of core protein allosteric modulators that modulate the HBV core protein at various points in the viral lifecycle. The company also develops microbiome program, a platform that includes the identification and selection process to strain isolation and growth under current good manufacturing practice conditions; and a patent pending delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. In addition, it engages in the development of product candidates for various disease indications, such as ulcerative colitis, Crohn's disease, irritable bowel syndrome, non-alcoholic steatohepatitis, immuno-oncology, and clostridium difficile infections by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of selected microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in Carmel, Indiana.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:ASMB
CUSIP92282210
Phone317-210-9311
Debt
Debt-to-Equity RatioN/A
Current Ratio7.43
Quick Ratio7.43
Price-To-Earnings
Trailing P/E Ratio-15.51
Forward P/E Ratio-9.07
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.02 million
Price / Sales105.47
Cash FlowN/A
Price / CashN/A
Book Value$5.62 per share
Price / Book6.65
Profitability
EPS (Most Recent Fiscal Year)($2.41)
Net Income$-42,800,000.00
Net Margins-457.20%
Return on Equity-66.34%
Return on Assets-40.23%
Miscellaneous
Employees79
Outstanding Shares25,450,000
Market Cap$930.07 million
Assembly Biosciences (NASDAQ:ASMB) Frequently Asked Questions
What is Assembly Biosciences' stock symbol?
Assembly Biosciences trades on the NASDAQ under the ticker symbol "ASMB."
How were Assembly Biosciences' earnings last quarter?
Assembly Biosciences Inc (NASDAQ:ASMB) issued its quarterly earnings results on Wednesday, August, 8th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.88) by $0.43. The biopharmaceutical company earned $3.22 million during the quarter, compared to the consensus estimate of $3.30 million. Assembly Biosciences had a negative return on equity of 66.34% and a negative net margin of 457.20%. View Assembly Biosciences' Earnings History.
When is Assembly Biosciences' next earnings date?
What price target have analysts set for ASMB?
4 brokers have issued 1-year price objectives for Assembly Biosciences' shares. Their predictions range from $45.00 to $75.00. On average, they anticipate Assembly Biosciences' share price to reach $61.00 in the next twelve months. This suggests a possible upside of 63.2% from the stock's current price. View Analyst Price Targets for Assembly Biosciences.
What is the consensus analysts' recommendation for Assembly Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Assembly Biosciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Assembly Biosciences.
Are investors shorting Assembly Biosciences?
Assembly Biosciences saw a decline in short interest during the month of July. As of July 31st, there was short interest totalling 428,692 shares, a decline of 28.3% from the July 13th total of 597,976 shares. Based on an average daily volume of 239,023 shares, the days-to-cover ratio is presently 1.8 days. Currently, 2.5% of the company's shares are short sold. View Assembly Biosciences' Current Options Chain.
Who are some of Assembly Biosciences' key competitors?
Some companies that are related to Assembly Biosciences include Madrigal Pharmaceuticals (MDGL), Endo International (ENDP), Horizon Pharma (HZNP), Evotec (EVTCY), Opko Health (OPK), Akcea Therapeutics (AKCA), Blueprint Medicines (BPMC), Intercept Pharmaceuticals (ICPT), Array Biopharma (ARRY), Ascendis Pharma A/S (ASND), Emergent Biosolutions (EBS), Heron Therapeutics (HRTX), The Medicines (MDCO), Mallinckrodt (MNK) and Ironwood Pharmaceuticals (IRWD).
Who are Assembly Biosciences' key executives?
Assembly Biosciences' management team includes the folowing people:
- Mr. Derek A. Small, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Uri A. Lopatin, Co-Founder, Chief Medical Officer and VP of R&D (Age 46)
- Dr. Richard J. Colonno, Exec. VP & Chief Scientific Officer of Virology Operations (Age 68)
- Mr. Thomas E. Rollins, Exec. Officer (Age 62)
- Mr. David J. Barrett CPA, Strategic Advisor Role (Age 42)
Has Assembly Biosciences been receiving favorable news coverage?
News headlines about ASMB stock have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Assembly Biosciences earned a coverage optimism score of 0.16 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.51 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. View Recent Headlines for Assembly Biosciences.
Who are Assembly Biosciences' major shareholders?
Assembly Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (12.03%), BlackRock Inc. (6.04%), Janus Henderson Group PLC (3.92%), Emerald Advisers Inc. PA (1.14%), Emerald Mutual Fund Advisers Trust (0.99%) and Baker BROS. Advisors LP (0.58%). Company insiders that own Assembly Biosciences stock include Derek A Small and William R Ringo. View Institutional Ownership Trends for Assembly Biosciences.
Which institutional investors are selling Assembly Biosciences stock?
ASMB stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Baker BROS. Advisors LP, BlueMountain Capital Management LLC, California Public Employees Retirement System, Victory Capital Management Inc., Millennium Management LLC and WINTON GROUP Ltd. View Insider Buying and Selling for Assembly Biosciences.
Which institutional investors are buying Assembly Biosciences stock?
ASMB stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, BlackRock Inc., Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, FMR LLC, Prosight Management LP, Jennison Associates LLC and Alps Advisors Inc.. View Insider Buying and Selling for Assembly Biosciences.
How do I buy shares of Assembly Biosciences?
Shares of ASMB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Assembly Biosciences' stock price today?
One share of ASMB stock can currently be purchased for approximately $37.38.
How big of a company is Assembly Biosciences?
Assembly Biosciences has a market capitalization of $930.07 million and generates $9.02 million in revenue each year. The biopharmaceutical company earns $-42,800,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Assembly Biosciences employs 79 workers across the globe.
How can I contact Assembly Biosciences?
Assembly Biosciences' mailing address is 11711 NORTH MERIDIAN STREET SUITE 310, CARMEL IN, 46032. The biopharmaceutical company can be reached via phone at 317-210-9311 or via email at [email protected]
MarketBeat Community Rating for Assembly Biosciences (NASDAQ ASMB)
MarketBeat's community ratings are surveys of what our community members think about Assembly Biosciences and other stocks. Vote "Outperform" if you believe ASMB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASMB will underperform the S&P 500 over the long term. You may vote once every thirty days.
